Wells Fargo & Company Hepion Pharmaceuticals, Inc. Transaction History

Wells Fargo & Company

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$0.31 - $1.06 $2 - $9	9 Added 1.73%	528 $0
Q4 2022 Feb 13, 2023	BUY	$0.27 - $11.9 $3 - $154	13 Added 2.57%	519 $0
Q3 2022 Nov 14, 2022	SELL	$0.51 - $10.4 $2 - $41	-4 Reduced 0.78%	506 $0
Q2 2022 Aug 12, 2022	BUY	$0.57 - $1.22 $23 - $50	41 Added 8.74%	510 $0
Q1 2022 May 16, 2022	BUY	$0.93 - $1.29 $0 - $1	1 Added 0.21%	469 $1,000
Q4 2021 Feb 14, 2022	BUY	$1.14 - $1.58 $1 - $1	1 Added 0.21%	468 $1,000
Q3 2021 Nov 15, 2021	SELL	$1.39 - $2.1 $34 - $52	-25 Reduced 5.08%	467 $1,000
Q2 2021 Aug 16, 2021	SELL	$1.56 - $2.26 $6 - $9	-4 Reduced 0.81%	492 $1,000
Q1 2021 May 13, 2021	BUY	$1.77 - $2.98 $504 - $849	285 Added 135.07%	496 $1,000
Q4 2020 Feb 09, 2021	BUY	$1.58 - $3.64 $243 - $560	154 Added 270.18%	211 $0
Q3 2020 Nov 05, 2020	BUY	$2.84 - $4.59 $139 - $224	49 Added 612.5%	57 $0
Q1 2020 May 14, 2020	BUY	$1.15 - $5.74 $9 - $45	8 New	8 $0

Ticker HEPA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,229,600
Market Cap $51.8M
Description
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.